Dow Jones
37.775,38 +22,07 (+0,06%) Nasdaq
15.601,50 -81,87 (-0,52%) Nikkei 225
37.068,35 -1.011,35 (-2,65%) EUR/USD
1,0637 -0,0009 (-0,09%) Bitcoin EUR
58.301,51 +790,52 (+1,37%) CMC Crypto 200
1.280,35 -32,27 (-2,46%)
Alaunos Therapeutics, Inc. (TCRT)
Dopo ore:
| Chiusura precedente | 1,2700 |
| Aperto | 1,2509 |
| Denaro | 1,1800 x 100 |
| Lettera | 1,2700 x 100 |
| Min-Max giorno | 1,2000 - 1,2750 |
| Intervallo di 52 settimane | 0,6000 - 10,5000 |
| Volume | |
| Media Volume | 121.236 |
| Capitalizzazione | 19,695M |
| Beta (5 anni mensile) | -0,36 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -33,0000 |
| Prossima data utili | 08 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireAlaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patientsCompany to wind down TCR-T Library Phase 1/2 trial and concurrently explore potential partnering opportunities for the hunTR® platform as well as broad strategic alternativesReducing headcount by approximately 60% while retaining key hunTR® R&D capabilities HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- A
- GlobeNewswire
Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Company will present at the 2nd Hawaii Global Summit on Thoracic Malignancies taking place June 27 – July 1, 2023. Alaunos Director of Translational Sciences Matthew Collinson-Pautz, Ph.D., will discuss the Company’s TCR-T therapy in sol
- GlobeNewswire
Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting
TCR-T cell therapy shows first-in-human response for non-viral TCR-T therapy; effectively targets high frequency TP53 and KRAS driver mutations across multiple solid tumor indicationsTreatment was well tolerated with a manageable safety profile and persistence of TCR-T cells in peripheral blood observed in all three treated patients at last follow-upProof-of-concept demonstrated for non-viral Sleeping Beauty cell engineering platform in effective manufacturing of TCR-T cell therapies with all pr
